

Preface

As the Editor-in-Chief of “Current Drug Research Reviews” (CDRR, online ISSN: 2589-9783, print ISSN: 2589-9775; formerly Current Drug Abuse Reviews), a peer-reviewed journal, I wish a warm welcome to all the readers to this new volume. CDRR is an international peer-reviewed journal, which publishes research articles, review articles and clinical studies on the design and development of new drugs, including drug targeting, medicinal chemistry, in-silico drug design, combinatorial chemistry, meta-analyses, drug abuse and addiction, drug-drug interactions and enzyme kinetics; species scaling and extrapolations; drug transporters; target organ toxicity and inter-individual variability in drug exposure-response; extrahepatic metabolism; bio-activation, reactive metabolites, high-throughput screening, drug targets and structure-activity relationships. The journal aims to cover the latest developments in all important aspects of drug design, delivery, development and research.



R.J. Dinis-Oliveira

CDRR is particularly helpful for all scientists involved in drug design and development, offering also a platform to publish articles focusing on antidotes and analytical diagnosis in attempt to assist clinical pharmacologists and toxicologists in the treatment of intoxications. The potentialities and procedures of laboratory techniques are also important fields for CDRR if they provide sufficient information to facilitate the interpretation of analytical results or to follow therapeutic drug monitoring in different biological samples and specific populations (e.g., pediatric, elderly, pregnant, obese and critically ill patients, etc.) to achieve maximum efficacy and by avoiding drug toxicity after dose adjustment of certain drugs with a narrow therapeutic window. This means that real case reports are welcome if they also offer advances and review the therapeutic protocols for specific intoxications. Book reviews are also published.

Currently, CDRR is indexed in (BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Scopus, MEDLINE/PubMed, EMBASE/Excerpta Medica, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO and Ulrich's Periodicals Directory) and has successfully completed 10 years of scientific publications.

In 2018, CDRR continued to devote particular focus to the *in vitro* and *in vivo* animal and human pharmacological and toxicological mechanisms of drugs covering a unique array of topics that are of interest to a broad biomedical and clinical sciences audience, including physicians and pharmacists. The field of drug research has seen remarkable advances in the past few years, with valuable contributions coming from a diverse array of disciplines including molecular biology, biochemistry, metabolism, nanotechnology cell biology, pharmacology, toxicology and translational medicine, to name a few. Synthesizing these diverse, up-to-date and exciting findings with ongoing advances in the field of drug research is an increasing challenge especially for those that ultimately have to teach them in faculties and universities during pre and post-graduation cycle of studies. However, with new and expanded capabilities it is challenging and also mandatory to provide appropriate meaning to that evidence and therefore CDRR also attempts to gather information to support or refute theories, and provide fact-based explanations with pre-clinical and clinical significance, always by fulfilling ethical and legal recommendations. Following this line, CDRR aims also to be scientifically updated to represent an alternative to textbooks ultimately focusing in translational medicine and we intent to follow a “comprehensive” perspective. The ability to search relevant literature will be even more important tomorrow than it is today due to the new technologies such as genomics, proteomics and metabolomics, novel *in vivo* and *in vitro* models, *in silico* and computational methods that have enabled greater insights into the pharmacokinetic and pharmacodynamic mechanisms of drugs. CDRR will be also particularly interested in pharmacogenomics aspects of therapeutics, namely target receptors, ion channels, enzymes, or transporters that could be an additional clinical factor aiming to personalized prescription. Thematic issues on the new psychoactive substances, anabolic steroids and nootropics will be welcome for next publications. Unravelling their pharmacokinetics and pharmacodynamics mechanisms, additive aspects, is a compelling need. As per usual procedure, all such submissions will be peer-reviewed. Moreover, as I truly believe, articles affording drug-related data in a balanced teaching-research perspective will certainly capture the interest of CDRR readers.

The Journal will further comprise an agenda listing relevant meetings and conferences taking place in a near future and we expect to attract scientifically sound manuscripts from all over the world making extensive use of color figures, illustrations, and tables to present concepts in a focused and didactic manner. Finally, CDRR editorial board aims to thankful to authors and reviewers, outstanding talented experts that have generously contributed with their knowledge to CDRR improvement.

Ricardo Jorge Dinis-Oliveira
(Editor-in-Chief)

University Institute of Health Sciences – CESPU, CrL.
Faculty of Medicine and UCIBIO-REQUIMTE - University of Porto.
Central de Gandra Street, 1317
4585-116 Gandra, PRD
Portugal

E-mails: ricardo.dinis@iucs.cespu.pt; ricardinis@med.up.pt